600368 Disclosed herein are compounds of formula (I), wherein the variables are defined in the specification； the use thereof in the treatment of neurodegenerative diseases, cerebral trauma, epilepsy, inflammatory disease, osteoporosis, cancers, Parkinson's disease, Alzheimer's disease, tauopathies, multiple sclerosis, schizophrenia, depression, substance dependency and attention deficit hyperactivity disorder； and an intermediate boronic ester compound of formula (VI-1). Specific embodiments of the compounds of formula (I) include: { 3-[2-(4-fluorophellyl)pyrazolo[1,5-a]pyridin-5-yl]phenyl} morpholin-4-ylmethanone, N-cyclopropyl-3-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-yl]benzamide, and 3-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-5-yl]-N-methylbenzamide
